OBJECTIVES: The Canadian Common Drug Review (CDR) is a national HTA agency that has been in existence for 10 years.  During this, the CDR has reviewed the clinical and cost-effectiveness of 188 drugs and provided 269 recommendations to the publically funded drug plans.  Of all the drugs reviewed over the past 10 years, 50.4% have received a positive recommendation and 49.6% have received a negative recommendation.  The objective of this analysis was to describe the success rate of each pharmaceutical manufacturer in terms of type of recommendation, time to recommendation, and time to listing in the provincial formularies. METHODS: The CDR Tracker database was used to analyze all CDR drug reviews from 2003 to the end of 2012.  There were a total of 189 reviews during this 10 year period.  All manufacturers that had three or more submissions with CDR were included in the analysis; 29 companies met this criterion. RESULTS: Of the 189 reviews and 29 companies analyzed, the positive recommendation rates ranged from 100% to 17%.  The top 5 most successful manufactures in terms of positive recommendations were Roche (100%), Abbott (100%), Bayer (83%), Gilead (80%), and Boehringer-Ingelheim (80%).  The average time to receive a CDR recommendation varied from 170 days to 248 days.  The manufacturers with the fastest time to recommendation are GSK, Abbott, Roche, Boehringer-Ingelheim, and Watson.  Time to reimbursement / formulary listings in all provinces ranged from 123 days to 593 days. CONCLUSIONS: This is the first analysis to describe the success rate of pharmaceutical manufacturers through the CDR.  There appears to high variability in all the metrics that were measured and further research into the determinants of variability is warranted.